association

Full identifier: http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#association

Assigned to 1 class:

Minted in Nanopublication

 RA7gbqitc- comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RA7gbqitc-...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "alendronate sodium tablets usp are a bisphosphonate indicated for treatment and prevention of osteoporosis in postmenopausal women 1 1 1 2 treatment to increase bone mass in men with osteoporosis 1 3 treatment of glucocorticoid induced osteoporosis 1 4 treatment of paget s disease of bone 1 5 limitations of use optimal duration of use has not been determined for patients at low risk for fracture consider drug discontinuation after 3 to 5 years of use 1 6 alendronate sodium tablets usp are indicated for the treatment of osteoporosis in postmenopausal women in postmenopausal women alendronate sodium tablets usp increase bone mass and reduces the incidence of fractures including those of the hip and spine vertebral compression fractures see clinical studies 14 1 alendronate sodium tablets usp are indicated for the prevention of postmenopausal osteoporosis see clinical studies 14 2 alendronate sodium tablets usp are indicated for treatment to increase bone mass in men with osteoporosis see clinical studies 14 3 alendronate sodium tablets usp are indicated for the treatment of glucocorticoid induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7 5 mg or greater of prednisone and who have low bone mineral density see clinical studies 14 4 alendronate sodium tablets usp are indicated for the treatment of paget s disease of bone in men and women treatment is indicated in patients with paget s disease of bone who have alkaline phosphatase at least two times the upper limit of normal or those who are symptomatic or those at risk for future complications from their disease see clinical studies 14 5 the optimal duration of use has not been determined the safety and effectiveness of alendronate sodium tablets usp for the treatment of osteoporosis are based on clinical data of four years duration all patients on bisphosphonate therapy should have the need for continued therapy re evaluated on a periodic basis patients at low risk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture re evaluated periodically" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA7gbqitc-... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-30T09:16:32.903+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA7gbqitc-... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RA7gbqitc-... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RA7gbqitc-... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RA7gbqitc-...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RA7gbqitc-... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RA7gbqitc-...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 30 Jun 2021, 07:16:32 UTC

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T07:16:32.903Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
alendronate sodium tablets usp are a bisphosphonate indicated for treatment and prevention of osteoporosis in postmenopausal women 1 1 1 2 treatment to increase bone mass in men with osteoporosis 1 3 treatment of glucocorticoid induced osteoporosis 1 4 treatment of paget s disease of bone 1 5 limitations of use optimal duration of use has not been determined for patients at low risk for fracture consider drug discontinuation after 3 to 5 years of use 1 6 alendronate sodium tablets usp are indicated for the treatment of osteoporosis in postmenopausal women in postmenopausal women alendronate sodium tablets usp increase bone mass and reduces the incidence of fractures including those of the hip and spine vertebral compression fractures see clinical studies 14 1 alendronate sodium tablets usp are indicated for the prevention of postmenopausal osteoporosis see clinical studies 14 2 alendronate sodium tablets usp are indicated for treatment to increase bone mass in men with osteoporosis see clinical studies 14 3 alendronate sodium tablets usp are indicated for the treatment of glucocorticoid induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7 5 mg or greater of prednisone and who have low bone mineral density see clinical studies 14 4 alendronate sodium tablets usp are indicated for the treatment of paget s disease of bone in men and women treatment is indicated in patients with paget s disease of bone who have alkaline phosphatase at least two times the upper limit of normal or those who are symptomatic or those at risk for future complications from their disease see clinical studies 14 5 the optimal duration of use has not been determined the safety and effectiveness of alendronate sodium tablets usp for the treatment of osteoporosis are based on clinical data of four years duration all patients on bisphosphonate therapy should have the need for continued therapy re evaluated on a periodic basis patients at low risk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture re evaluated periodically
Leoni Bücken
2021-06-30T07:16:32.903Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T07:16:32.903Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T07:16:32.903Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T07:16:32.903Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T07:16:32.903Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T07:16:32.903Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T07:16:32.903Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)